The findings of this proof of principle study may have the potential to open up an entirely new window of opportunity to: (a) predict breast cancer and (b) allow monitoring of preventive and therapeutic hormonal therapies (tamoxifen or aromatase inhibitors) in breast cancer. This evidence concerns the gene CYP19A1 and breast carcinoma.